Shots:

• The P-I & II (MajesTEC-1) study evaluates teclistamab in patients with r/r MM who had received three prior lines of therapy & were triple-class exposed
• Results: @median follow-up of 8mos., ORR (62%), m-DoR (not reached) & 88% of responders were alive and continuing treatment, responses were durable and deepened over time, the median time to first confirmed response was 1.2mos. in responded patients
• Additionally, 80% of patients achieved a VGPR or better; CR (29%); sCR (21%), 25% achieved MRD negativity while MRD negativity rate (42%) in patients who achieved CR or better, PFS rate (59%) @9mos., m-OS was not reached, tolerable safety profile, and no patients required a dose reduction

Ref: PR Newswire | Image: Janssen